These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35196473)

  • 1. Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility.
    Patel N; Blumenthal J; Dubé MP; Hood A; Bolan R; Morris S
    LGBT Health; 2022 Apr; 9(3):199-206. PubMed ID: 35196473
    [No Abstract]   [Full Text] [Related]  

  • 2. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz RJ; Reirden D; Malhotra M; Glenny C; Harding P; Powell T; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Dec; 38(12):939-943. PubMed ID: 35815468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
    Patel N; Morris S; Burke L; Chow K; Pacheco D; Anderson P; Stancyzk F; Blumenthal J
    Br J Clin Pharmacol; 2024 Oct; 90(10):2360-2365. PubMed ID: 38646796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
    Yager JL; Anderson PL
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV.
    Senneker T
    Br J Clin Pharmacol; 2024 Oct; 90(10):2366-2382. PubMed ID: 38866600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
    Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
    Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
    Solomon MM; Lama JR; Glidden DV; Mulligan K; McMahan V; Liu AY; Guanira JV; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Burns DN; Grant RM;
    AIDS; 2014 Mar; 28(6):851-9. PubMed ID: 24499951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
    Solomon MM; Schechter M; Liu AY; McMahan VM; Guanira JV; Hance RJ; Chariyalertsak S; Mayer KH; Grant RM;
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):281-6. PubMed ID: 26413853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam.
    Doan AH; Vu CMH; Nguyen TT; Green KE; Phan HTT; Janamnuaysook R; Vu BN; Le TM; Do KQ; Tran TT; Ngo TM; Basu L; Tran LK; Humeau Z
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25996. PubMed ID: 36225133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.
    Drak D; Barratt H; Templeton DJ; O'Connor CC; Gracey DM
    PLoS One; 2019; 14(1):e0210106. PubMed ID: 30653509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
    Anderson PL; Reirden D; Castillo-Mancilla J
    J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 3(Suppl 3):S230-4. PubMed ID: 27429188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
    Trang TP; Dong BJ; Kojima N; Klausner JD
    Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
    Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
    PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.